Literature DB >> 12054412

Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.

Anthony B Hodsman1, David A Hanley, Robert Josse.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12054412      PMCID： PMC111217     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  25 in total

1.  Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors:  M C Nevitt; D E Thompson; D M Black; S R Rubin; K Ensrud; A J Yates; S R Cummings
Journal:  Arch Intern Med       Date:  2000-01-10

2.  Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.

Authors:  T Schnitzer; H G Bone; G Crepaldi; S Adami; M McClung; D Kiel; D Felsenberg; R R Recker; R P Tonino; C Roux; A Pinchera; A J Foldes; S L Greenspan; M A Levine; R Emkey; A C Santora; A Kaur; D E Thompson; J Yates; J J Orloff
Journal:  Aging (Milano)       Date:  2000-02

3.  Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group.

Authors:  K E Ensrud; D E Thompson; J A Cauley; M C Nevitt; D M Kado; M C Hochberg; A C Santora; D M Black
Journal:  J Am Geriatr Soc       Date:  2000-03       Impact factor: 5.562

Review 4.  Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis.

Authors:  W J Gillespie; D A Henry; D L O'Connell; J Robertson
Journal:  Cochrane Database Syst Rev       Date:  2000

5.  Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis.

Authors:  C M Klotzbuecher; P D Ross; P B Landsman; T A Abbott; M Berger
Journal:  J Bone Miner Res       Date:  2000-04       Impact factor: 6.741

6.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

7.  Risk of mortality following clinical fractures.

Authors:  J A Cauley; D E Thompson; K C Ensrud; J C Scott; D Black
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

8.  Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis.

Authors:  R G Crilly; R J Sebaldt; A B Hodsman; J D Adachi; J P Brown; C H Goldsmith; D A Hanley; W O Olszynski; L G Ste-Marie; G F Stephenson
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

9.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Authors:  M R McClung; P Geusens; P D Miller; H Zippel; W G Bensen; C Roux; S Adami; I Fogelman; T Diamond; R Eastell; P J Meunier; J Y Reginster
Journal:  N Engl J Med       Date:  2001-02-01       Impact factor: 91.245

10.  Risk of new vertebral fracture in the year following a fracture.

Authors:  R Lindsay; S L Silverman; C Cooper; D A Hanley; I Barton; S B Broy; A Licata; L Benhamou; P Geusens; K Flowers; H Stracke; E Seeman
Journal:  JAMA       Date:  2001-01-17       Impact factor: 56.272
View more
  16 in total

Review 1.  Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis.

Authors:  T Saito; J M Sterbenz; S Malay; L Zhong; M P MacEachern; K C Chung
Journal:  Osteoporos Int       Date:  2017-08-02       Impact factor: 4.507

2.  Osteoporosis risk assessment and ethnicity: validation and comparison of 2 clinical risk stratification instruments.

Authors:  Alvah R Cass; Angela J Shepherd; Carol A Carlson
Journal:  J Gen Intern Med       Date:  2006-06       Impact factor: 5.128

3.  A novel effervescent formulation of oral weekly alendronate (70 mg) improves persistence compared to alendronate tablets in post-menopausal women with osteoporosis.

Authors:  Andrea Giusti; Gerolamo Bianchi; Antonella Barone; Dennis M Black
Journal:  Aging Clin Exp Res       Date:  2021-01-15       Impact factor: 3.636

Review 4.  2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.

Authors:  Jacques P Brown; Robert G Josse
Journal:  CMAJ       Date:  2002-11-12       Impact factor: 8.262

Review 5.  The epidemiology of osteoporosis.

Authors:  Michael A Clynes; Nicholas C Harvey; Elizabeth M Curtis; Nicholas R Fuggle; Elaine M Dennison; Cyrus Cooper
Journal:  Br Med Bull       Date:  2020-05-15       Impact factor: 4.291

6.  Development and internal validation of the male osteoporosis risk estimation score.

Authors:  Angela J Shepherd; Alvah R Cass; Carol A Carlson; Laura Ray
Journal:  Ann Fam Med       Date:  2007 Nov-Dec       Impact factor: 5.166

7.  Information needs in the management of osteoporosis in family practice: an illustration of the failure of the current guideline implementation process.

Authors:  Susan B Jaglal; Warren J McIsaac; Gillian Hawker; June Carroll; Liisa Jaakkimainen; Suzanne M Cadarette; Cathy Cameron; Dave Davis
Journal:  Osteoporos Int       Date:  2003-07-22       Impact factor: 4.507

Review 8.  What is osteoporosis?

Authors:  C Christodoulou; C Cooper
Journal:  Postgrad Med J       Date:  2003-03       Impact factor: 2.401

9.  Functional limitations and poor physical performance as independent risk factors for self-reported fractures in older persons.

Authors:  V S Stel; S M F Pluijm; D J H Deeg; J H Smit; L M Bouter; P Lips
Journal:  Osteoporos Int       Date:  2004-03-11       Impact factor: 4.507

10.  Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis.

Authors:  Ariane Höer; Cornelia Seidlitz; Holger Gothe; Guido Schiffhorst; Melvin Olson; Peyman Hadji; Bertram Häussler
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.